GlassScriptPhysician profile
Joel S Goldberg
NPI 1699714402
$3,539.93
in general payments reported to CMS, 2019-2025
33 companies · $873 in 2025
The $873 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $268 · 2021: $555 · 2022: $742 · 2023: $457 · 2024: $514 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $869.47 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $775.65 | 2021-2025 | |
| Novo Nordisk INC | $300.64 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $215.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $164.18 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $158.94 | 2021-2023 | Rexulti |
| Medtronic, INC. | $122.27 | 2021-2022 | |
| Braeburn INC. | $96.23 | 2023-2025 | Brixadi |
| Orexo US, INC. | $80.61 | 2022-2023 | Zubsolv |
| Exact Sciences Corporation | $66.34 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $59.04 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.84 | 2024-2025 | Caplyta |
| Pfizer INC. | $57.80 | 2023-2025 | |
| Corium, LLC | $56.46 | 2023 | Azstarys, Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.79 | 2019-2025 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $37.73 | 2024-2025 | Sublocade |
| Biohaven Pharmaceuticals, INC. | $35.61 | 2021 | |
| Amgen INC. | $34.35 | 2024 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $29.86 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $28.58 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $28.41 | 2022 | |
| Cipher Pharmaceuticals US LLC | $27.05 | 2025 | Natroba, Spinosad |
| Lilly USA, LLC | $25.00 | 2025 | Mounjaro, Zepbound |
| Alkermes, INC. | $23.98 | 2021 | |
| Eisai INC. | $19.60 | 2020 | |
| Verona Pharma, INC. | $19.02 | 2025 | Ohtuvayre |
| Optinose US, INC. | $18.38 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.89 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.59 | 2020 | |
| Astellas Pharma US INC | $14.57 | 2019 | |
| Pear Therapeutics (US), INC. | $12.91 | 2021 | |
| Bausch Health US, LLC | $11.87 | 2021 | |
| Philips North America LLC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.